Benyunes Mc

Use of interleukin-2 after bone marrow transplantation

A. Fefer, A. York, J. Thompson, 1995 .

Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.

J. Thompson, A. Fefer, C. Lindgren, 1993, Experimental hematology.

Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.

J. Thompson, John A Thompson, M. Benyunes, 1995, Bone marrow transplantation.

Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.

J. Thompson, M. Benyunes, F. Petersen, 1993, Bone marrow transplantation.

Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.

J. Thompson, G. Sale, M. Benyunes, 1996, Bone marrow transplantation.

Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.

P. Lange, J. Thompson, C. Collins, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.